Everything below concerns CJC-1295. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-10. Numbers and descriptions here follow the published literature rather than marketing material.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
=== Generation of pharmaceutical cocrystals === Supercritical fluids act as a new medium for the generation of novel crystalline forms of APIs (Active Pharmaceutical Ingredients) named as pharmaceutical cocrystals. Supercritical fluid technology offers a new platform that allows a single-step generation of particles that are difficult or even impossible to obtain by traditional techniques. The generation of pure and dried new cocrystals (crystalline molecular complexes comprising the API and one or more conformers in the crystal lattice) can be achieved due to unique properties of SCFs by using different supercritical fluid properties: supercritical CO2 solvent power, anti-solvent effect and its atomization enhancement.
When tungsten filaments were introduced, about 50 million lamp sockets existed in the US. In 1914, 88.5 million lamps were used, (only 15% with carbon filaments), and by 1945, annual sales of lamps were 795 million (more than 5 lamps per person per year).
Protein deficiency and malnutrition (PEM) can lead to a variety of ailments, including intellectual disability and kwashiorkor. Symptoms of kwashiorkor include apathy, diarrhea, inactivity, failure to grow, flaky skin, fatty liver, and edema of the belly and legs. This edema is explained by the action of lipoxygenase on arachidonic acid to form leukotrienes and the normal functioning of proteins in fluid balance and lipoprotein transport. PEM is fairly common worldwide in both children and adults and accounts for 6 million deaths annually. In the industrialized world, PEM is predominantly seen in hospitals, is associated with disease, or is often found in the elderly.
Sources: en.wikipedia.org
== History == The concept of electrostatically trapping ions in an orbit around a central spindle was developed by Kenneth Hay Kingdon in the early 1920s. The Kingdon trap consists of a thin central wire and an outer cylindrical electrode. A static applied voltage results in a radial logarithmic potential between the electrodes. In 1981, Knight introduced a modified outer electrode that included an axial quadrupole term that confines the ions on the trap axis. Neither the Kingdon nor the Knight configurations were reported to produce mass spectra. In 1986, Professor Yuri Konstantinovich Golikov in USSR developed theory of ion motion in quadro-logarithmic potential, and filed for patents in USSR for its use in a time-of-flight analyzer. Golikov, leading a team at the St. Petersburg State Pedagogical University's Radiophysics Faculty, laid the theoretical groundwork for Orbitrap technology as one of inventors in USSR Inventor's certificate No. 1247973 in 1986. Golikov later remarked "Based on my ideas, analytical instruments with record parameters were built, but unfortunately not in Russia, but abroad." Contrary to popular belief, Alexander Makarov is not the original inventor of quadro-logarithmic potential which was known since 1950s. Reflecting on his early interaction with Golikov, Alexander Makarov recalled, "As a fifth-year student at MIPT, I entered one of the numerous rooms at the Polytechnic Institute, where I was met by Yuri Konstantinovich Golikov.
Narrated by Julie Berry, produced by Jeremy Bugler, directed by Richard Klein, made by Fulmar Television & Film 4 September Walking on Water, about surfing, with Ken Bradshaw, Edward Coventry, Viscount Deerhurst; Waimea Bay has the largest ridable waves in the world, with 50 feet waves; the waves originate from Japan; Mark Foo, who later drowned that year at Mavericks, California; Huntington Beach, California, known as Surf City. Directed by Steve Stevenson, produced by Mike Wallington, made by Parvenu Productions 11 September The Cyborg Cometh, Austrian Manfred Clynes invented the term cyborg for NASA in the 1950s; Prof Donna Haraway, author of the 1985 A Cyborg Manifesto; the nascent internet, and SF Net; Mike Browne, who had a skiing accident in 1993 making him paraplegic, the founder of Snow and Rock, now owned by Cotswold Outdoor; Lisa Jean Moore, the semen industry, techno-semen, and The Sperm Bank of California; prenatal testing; David Bentley of the MRC's Human Genome Mapping Project at the Sanger Centre (now the Wellcome Sanger Institute).
== In popular culture == The company's direct analysis in real time (DART) mass spectrometry system has appeared on the television program CSI: NY. The JEOL transmission electron microscope JEM 1011 was a base platform for Prometheus (2012 film) science lab microscope.
A cannabinoid receptor modulator is a compound that bind to the cannabinoid receptors, which are receptors in the human body that regulate multiple physiological responses, including pain sensation, mood regulation, and appetite. The two main targets of cannabinoid receptors modulators are cannabinoid receptor 1 (CBR1) and cannabinoid receptor 2 (CBR2). By stimulating or inhibiting these receptors, the modulators can achieve different therapeutic effects, such as relieving pain, reducing vomiting, improving appetite and maintaining muscle tone. Dronabinol, nabiximol, cannabidiol and nabilone are cannabinoid receptor modulators marketed as drugs for various therapeutic uses. These drugs also share some common adverse effects, including dizziness, headache, alteration in mental state, and diarrhoea. Recent research studies have explored other therapeutic potentials of the modulators, such as the antitumor effect of cannabidiol. Other cannabinoid receptor modulators are also under investigations.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.